Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.04+0.03 (+2.97%)
Close on Nov 18, 2026Market cap $13.87MP/E –Yield 0.00%
Tvardi Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tvardi Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$27.21M. For fiscal 2025 it was -$26.75M. The highest annual figure on record is $5.39M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.75M | – |
| FY2024 | Dec 31, 2024 | -$28.11M | – |
| FY2023 | Dec 31, 2023 | -$121.50M | – |
| FY2022 | Dec 31, 2022 | -$87.54M | – |
| FY2021 | Dec 31, 2021 | -$89.08M | -1754.3% |
| FY2020 | Dec 31, 2020 | $5.39M | – |
| FY2019 | Dec 31, 2019 | -$111.68M | – |
| FY2018 | Dec 31, 2018 | -$77.38M | – |
| FY2017 | Dec 31, 2017 | -$59.49M | – |
| FY2016 | Dec 31, 2016 | -$58.40M | – |
| FY2015 | Dec 31, 2015 | -$25.19M | – |
| FY2014 | Dec 31, 2014 | -$18.07M | – |
| FY2013 | Dec 31, 2013 | -$237.00K | – |
| FY2012 | Dec 31, 2012 | -$6.24M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.63M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.05M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.59M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.94M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.87M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.35M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.80M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.68M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.67M | – |
| Q4 FY2023 | Dec 31, 2023 | -$32.61M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.90M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.65M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.31M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.85M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.47M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.52M | -142.8% |
| Q3 FY2021 | Sep 30, 2021 | -$1.12M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.56M | – |
| Q4 FY2020 | Dec 31, 2020 | $78.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$17.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.88M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.97M | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.43M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$23.13M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.98M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.47M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.81M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.12M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.57M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.96M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.63M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.33M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.32M | – |
| Q3 FY2016 | Sep 30, 2016 | -$11.77M | – |
See a number that looks wrong?